JG
NVLN

Jefferies Group’s Novelion Therapeutics Inc. Common Shares NVLN Stock Holding History

Jefferies Group’s Portfolio NVLN Stock Details NVLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-35,156
Closed -$296K – 2795
2016
Q4 		$296K Buy
+35,156
New +$311K ﹤0.01% 1774

Other funds holding NVLN

BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return
HVC
Healthcare Value Capital Woodcliff Lake, New Jersey $50.7M AUM 24.72% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
HCM
Highbridge Capital Management New York $4.11B AUM 26.03% 1-Year Est. Return
KCM
Kingstown Capital Management New York $30.4M AUM 3.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AA
Ancora Advisors Cleveland, Ohio $5.19B AUM 23.19% 1-Year Est. Return

Jefferies Group's NVLN Position: Q1 2017 in Review

Jefferies Group sold out of Novelion Therapeutics Inc. Common Shares (NVLN) in Q1 2017, closing a stake of 35,156 shares — an estimated $296K sold.

Jefferies Group first reported a position in NVLN in Q4 2016 and held it in 1 quarter. The position peaked at $296K in Q4 2016. 66 funds tracked by Wall St. Rank hold NVLN as of Q1 2017.

  • Jefferies Group reported no remaining Novelion Therapeutics Inc. Common Shares position as of Q1 2017 after selling out during the quarter.
  • Jefferies Group sold 35,156 Novelion Therapeutics Inc. Common Shares shares in Q1 2017, an estimated $296K.
  • Jefferies Group first reported a position in Novelion Therapeutics Inc. Common Shares in Q4 2016 and held it in 1 quarter.
  • Jefferies Group's Novelion Therapeutics Inc. Common Shares position peaked at $296K in Q4 2016.
  • 66 funds tracked by Wall St. Rank held Novelion Therapeutics Inc. Common Shares as of Q1 2017.

Based on Jefferies Group's 13F filing for Q1 2017, filed 15 May 2017.